Deals
Angelini Pharma to Buy Catalyst in Deal Worth $4.1 Billion
The Angelini Pharma office in Ancona, Italy.
Photographer: Geraldine Hope Ghelli/The Washington Post/Getty ImagesItalian drugmaker Angelini Pharma SpA agreed to buy Catalyst Pharmaceuticals Inc. for $4.1 billion as it looks to grow in the US and build a footprint in rare diseases.
Angelini Pharma will pay $31.50 per share in cash for Catalyst, a 21% premium to the US-listed company’s closing share price on April 22, it said in a statement Thursday. Bloomberg previously reported on the potential deal.